Inhibitor Therapeutics, Inc.
INTI
$0.0514
-$0.0086-14.33%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.38% | -1.04% | -32.07% | 25.96% | 38.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.56% | 7.07% | -21.20% | 23.04% | 200.59% |
| Operating Income | -16.56% | -7.07% | 21.20% | -23.04% | -200.59% |
| Income Before Tax | -21.80% | -9.96% | 23.35% | -26.89% | -109.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.80% | -9.96% | 23.35% | -26.89% | -109.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.80% | -9.96% | 23.35% | -26.89% | -109.44% |
| EBIT | -16.56% | -7.07% | 21.20% | -23.04% | -200.59% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -22.06% | -7.69% | 23.68% | -29.03% | -118.43% |
| Normalized Basic EPS | -23.81% | -12.50% | 25.00% | -25.00% | -425.00% |
| EPS Diluted | -22.06% | -7.69% | 23.68% | -29.03% | -119.94% |
| Normalized Diluted EPS | -23.81% | -12.50% | 25.00% | -25.00% | -425.00% |
| Average Basic Shares Outstanding | 0.17% | 0.18% | 0.21% | 0.17% | -48.52% |
| Average Diluted Shares Outstanding | 0.17% | 0.18% | 0.21% | 0.17% | -48.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
